Regeneron announces analyses from Phase 3 C-Post trial
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Merck & Co (MRK) Announces the Approval of ENFLONSIA
Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc. (NYSE:MRK) announced that the Advisory Committee on Immunization Practices has approved ENFLONSIA for preventing respiratory syncytial virus in infants younger than 8 months. The recommendation is provisional and is pending the final approval of the CDC Director or the Health and Human Services Secretary. Merck & Co., Inc. (NYSE:MRK) noted that ENFLONSIA is the first and only RSV preventive option administered to infants using the same dose regardless of weight, simplifying dosing logistics. Moreover, earlier this month, the FDA approved ENFLONSIA based on the strong clinical trial data from the Phase 2b/3 CLEVER and Phase 3 SMART trials. The results showed a 60.5% reduction in medically attended RSV lower respiratory infections and an 84.3% reduction in RSV-associated hospitalizations. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that operates through two main business segments including the Pharmaceuticals and Animal Health Segments. It is known for Keytruda and Gardasil, which are the main sources of the company's revenue. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
UBS Sees Strong Sales Outlook for Eli Lilly's Zepbound and Mounjaro
Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating and $1,050 price target on Eli Lilly & Company (NYSE:LLY), pointing to the pharmaceutical company's dominant position in the market for treating obesity. Pixabay/Public Domain Sales estimates for Eli Lilly & Company (NYSE:LLY)'s weight-loss treatment Zepbound may surpass market expectations by about 15%, according to the investment bank's analysis, while estimates for the diabetes prescription Mounjaro are in line with current market projections. In general, UBS expects Eli Lilly's quarterly sales to exceed expectations by 2%. According to UBS, the company's next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly & Company (NYSE:LLY)'s second-quarter earnings would briefly benefit from CVS Health's formulary shift. Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world's largest pharmaceutical companies. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
a day ago
- Yahoo
Novo Nordisk Teams With WeightWatchers to Expand Wegovy Access
Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on June 26 that it will collaborate with WeightWatchers to begin distributing the bestselling weight-loss medication Wegovy, beginning July 1. The agreement allows cash-paying patients to purchase a month's supply of Wegovy for $299 at the Danish pharmaceutical company's Novocare pharmacy. Novo's other telehealth partners will also be able to provide the one-time fee through July 31. Pixabay/Public Domain Compounded forms of semaglutide, the active component of Wegovy and other Novo Nordisk A/S (NYSE:NVO) medications, are no longer available from WeightWatchers, which has emerged from bankruptcy. According to Evan Seigerman, an analyst at BMO Capital Markets, the collaboration enables WeightWatchers to revive its weight-loss medication approach while also assisting Novo Nordisk A/S (NYSE:NVO) in gaining patients who have been using compounded forms of the medication. Novo Nordisk A/S (NYSE:NVO) is a prominent global healthcare company that focuses on treating rare diseases, diabetes, and obesity. With 48,000 workers spread across more than 168 countries, Novo Nordisk is well-known for its pharmaceuticals, which include Wegovy, Rybelsus, and Ozempic. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
